This show marked more than a month after Cramer discussed pharmaceuticals and diagnostics devices firm Abbott Laboratories ...
(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking ...
Our fourth annual, two-day international event gathers top executives across commercial real estate and life sciences to dive into biotech growth, facilities of the future, innovative lab development, ...
Exact Sciences Corporation (EXAS) received a fresh analysis from Barclays analyst Luke Sergott, who on November 21, 2025, assigned the stock an Equal-Weight rating. This update highlights a price ...
Fintel on MSN
Barclays Downgrades Exact Sciences (EXAS)
Fintel reports that on November 21, 2025, Barclays downgraded their outlook for Exact Sciences (NasdaqCM:EXAS) from ...
The futures are trading higher as we get ready to close out a volatility-filled week that saw a massive roller coaster ride ...
Exact Sciences Corporation (NASDAQ: EXAS) received an Equal-Weight rating from Wells Fargo analyst Brandon Couillard. This change in outlook indicates a cautious stance on the stock’s performance ...
The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer ...
Madison-based Exact Sciences will be acquired by Abbott Laboratory for roughly $23 billion in a deal that was announced Nov.
Abbott's $23B Exact Sciences deal adds short-term risk and earnings dilution. Click here to read what this means for ABT ...
Successful tech-based companies become so in different ways, a phenomenon on display of late with the announced $23 billion acquisition of Wisconsin’s Exact Sciences by Illinois-based Abbott ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback